INS and glucose measurement: Importantly, a single AAV-hBSCL2 injection could restore visceral WAT development, improve hyperglycaemia, decrease serum TG levels, and promote insulin sensitivity/glucose tolerance in our pre-clinical SKO mouse model of congenital lipodystrophy.